id stringclasses 6
values | label stringclasses 6
values | recordType stringclasses 5
values | journal stringclasses 5
values | published stringdate 2025-01-01 00:00:00 2026-07-01 00:00:00 | pmid int64 39.6M 42.5M | doi stringclasses 5
values | testArticle stringclasses 6
values | participants float64 0 94 ⌀ | duration stringclasses 3
values | reportedOutcome stringclasses 6
values | statedLimit stringclasses 6
values | interestDeclaration stringclasses 6
values | gates.compoundedArticle stringclasses 3
values | gates.humanAdministration stringclasses 3
values | gates.comparator stringclasses 3
values | gates.equivalenceTested stringclasses 2
values | gates.independentOfStake stringclasses 3
values | gateNotes.independentOfStake stringclasses 1
value | sourceUrl stringclasses 6
values |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
chun-2025 | Chun 2025 real-world cohort | retrospective cohort | Diabetes, Obesity & Metabolism | 2025-03 | 39,776,038 | 10.1111/dom.16162 | Compounded semaglutide with cyanocobalamin, once weekly, subcutaneous | 94 | 3 months | 4.11 kg (SD 2.77), or 4.57 % of body weight (SD 2.96) | No control group, single commercial site, underlying data available on request only. The paper's title omits the cyanocobalamin its abstract reports. | All authors have received salary support from Restore Hyperwellness, the wellness chain whose customers were studied. | pass | pass | stop | stop | stop | null | https://doi.org/10.1111/dom.16162 |
heor-self-experiment-2025 | HEOR analysis with one participant | self-experiment | International Journal of Pharmaceutical Compounding | 2025-01 | 39,921,911 | null | Compounded tirzepatide, weekly | 1 | approximately 4 weeks | Not extracted here; the record is reported by its own author, who was the sole participant. | One participant, no control, no blinding. Sole affiliation is a one-person consultancy; the journal is published for the compounding industry. The paper states it is the first article focused on compounded tirzepatide. | Author and participant are the same person; published in the compounding industry's own journal. | pass | pass | stop | stop | partial | Coded partial rather than stop, and the difference matters. The sole affiliation is a one-person consultancy and the venue is the compounding industry's own journal, so a tie to one side of the comparison is disclosed and real. What is not established is that the author, a funder or an employer sells a compounded GLP-1... | https://pubmed.ncbi.nlm.nih.gov/39921911/ |
lilly-b12-impurity-2026 | Novel tirzepatide/B12 impurity | laboratory analysis | Expert Opinion on Drug Safety | 2026-05 | 42,010,938 | 10.1080/14740338.2026.2663185 | Ten samples of compounded tirzepatide with B12 from compounding pharmacies, medspas and telehealth providers across seven US states | 0 | null | Potency down to 43 % of the labelled amount; a previously unknown tirzepatide-B12 adduct at up to 10 % of total polypeptide content, with NMR showing altered tirzepatide structure. | Ten samples. Establishes that the adduct occurs and is widespread among products tested; does not measure how often, and tested no people. Clinical significance unknown, and the authors say so. | This manuscript was funded by Eli Lilly and Company; all five authors are Lilly employees. Lilly manufactures the approved tirzepatide products. | pass | stop | partial | partial | stop | null | https://doi.org/10.1080/14740338.2026.2663185 |
novo-immunogenicity-2026 | Impurities and potential immunogenicity | laboratory analysis | Pharmaceutical Research | 2026-07 | 42,533,250 | 10.1007/s11095-026-04146-9 | Products from 36 commercial suppliers across four continents, including 13 injectable compounded semaglutide products, alongside follow-on and oral products | 0 | null | Every compounded and follow-on sample showed an impurity profile distinct from the originator, including amino-acid deletions and additions and unidentified impurities. Under light exposure, compounded semaglutide diverged significantly in strength, total impurities and high-molecular-weight protein. | The impact of these impurity profiles on safety and efficacy has not been tested clinically; increased immunogenicity is potential, not demonstrated. Follow-on products are a separate class from US compounded products and their findings must not be merged. | Every author is a Novo Nordisk employee and shareholder, or was at the time of the work. Novo Nordisk supplied the originator comparators and manufactures the approved semaglutide and liraglutide products. | pass | stop | pass | partial | stop | null | https://doi.org/10.1007/s11095-026-04146-9 |
faers-2026 | FAERS disproportionality analysis | pharmacovigilance | Expert Opinion on Drug Safety | 2026-03 | 40,285,721 | 10.1080/14740338.2025.2499670 | 81,078 GLP-1 receptor agonist reports 2018-2024, of which 707 involved compounded products | null | 2018-2024 | Elevated reporting odds ratios for preparation errors (48.92; 12.63-189.6), contamination (19.00; 4.24-85.03), compounding and manufacturing issues (8.51; 5.17-14.0) and hospitalisation (2.35; 1.94-2.83); lower for administration errors (0.29) and dosing errors (0.24). | A reporting odds ratio is a disproportionality measure, not a risk estimate, and does not establish cause. The database is voluntary and unverified, the denominator is unknown, and the window coincides with sustained press attention. The authors state the study was not designed to show cause and effect. | Geisinger and Binghamton University, with no product on either side. The lead author sits on the board of the Partnership for Safe Medicines, which contributed $850 to the work; a co-author was on a Pfizer- and Lilly-supported research team years earlier. Disclosures, not disqualifications. | partial | partial | partial | stop | partial | null | https://doi.org/10.1080/14740338.2025.2499670 |
ada-statement-2025 | American Diabetes Association statement | position statement | Diabetes Care | 2025-02 | 39,620,926 | 10.2337/dci24-0091 | None. A professional-society position, not a study. | 0 | null | No US Pharmacopeia monograph exists for semaglutide or tirzepatide, so no external standard defines a correct compounded preparation and no required test verifies one. Some compounders add vitamin B12 or B6, and some use salt forms in place of the base used in approved products. | A position statement is not a measurement. It establishes the absent standard, not an outcome in any patient. | Funded from ADA general revenue; the statement declares that no other entity, including industry, provided support. The only industry-free source in this set. | stop | stop | stop | stop | pass | null | https://doi.org/10.2337/dci24-0091 |
Compounded GLP-1 products: six published sources coded for human evidence, comparator and independence
An editorially selected audit of six published sources bearing on whether compounded GLP-1 products have the same human evidence as approved products. Each source is coded against five explicit gates covering the test article, human administration, comparator, equivalence and independence.
Read the evidence-led article: https://lifesco.re/edge/do-compounded-glp-1-drugs-have-the-same-human-evidence/
Archived version and DOI: https://doi.org/10.5281/zenodo.22017428
What the coding shows
- Two of the six audited sources administered a compounded product to a person.
- None tested clinical equivalence or bioequivalence against the approved product.
- One source passed the audit's independence gate outright.
Scope and responsible use
This is not a systematic review or literature census. It is not medical, dosing, sourcing or purchase advice, a safety verdict, or proof that an untested claim is false.
The complete selection rules, gate definitions, limitations, independence
statement and versioning policy travel with the data in PROTOCOL.md. The
CSV files are intended for tabular exploration; the JSON files preserve the
full structured record and source notes.
Provenance
- Publisher: lifescore Edge
- Editorial methodology and correction route: https://lifesco.re/edge/methodology/
- Dataset version: 1.0.0
- Evidence reviewed: 2026-08-18
- Licence: CC BY 4.0, limited to the original selection, scheme, coding and text described in
PROTOCOL.md
Citation
@dataset{lifescore_compounded_glp1_evidence_audit_1_0_0,
author = {{lifescore}},
title = {Compounded GLP-1 products: six published sources coded for human evidence, comparator and independence},
year = {2026},
version = {1.0.0},
publisher = {lifescore},
doi = {10.5281/zenodo.22017428},
url = {https://doi.org/10.5281/zenodo.22017428}
}
- Downloads last month
- 24